2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 952

Cognitive Behavioral Therapy and Milnacipran in Combination Appears to Be More Efficacious Than Either Therapy Alone
Abstract Number: 1878

Cognitive Manifestations of Fibromyalgia and Lupus
Abstract Number: 2003

Colchicine As a Therapeutic Option in Periodic Fever Aphtous Stomatitis, Pharingitis Syndrome. and Cervical Adenitis (PFAPA)
Abstract Number: 165

Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study
Abstract Number: 1912

Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Abstract Number: 197

Collapsing Glomerulopathy in Collagen Vascular-Like Disease
Abstract Number: 901

Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Abstract Number: 2390

Color Doppler Ultrasonography an Alternative to CT/MR Angiography for Identifying Large Vessel Involvement in Giant Cell Arteritis?
Abstract Number: 118

Colour Doppler Sonography of the Knee Joint: A Useful Tool to Discriminate Arthritis From Osteoarthritis ?
Abstract Number: 445

Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study
Abstract Number: 1645

Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases
Abstract Number: 2112

Combination of Magnetic Resonance Imaging (MRI)-Proven Osteitis with 2010 RA Classification Criteria Improves the Diagnostic Probability of Rheumatoid Arthritis (RA)
Abstract Number: 1414

Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: A 12-Month Open-Labeled Trial
Abstract Number: 2074

Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and Methotrexate On Collagen-Induced Arthritis in Mice
Abstract Number: 1135

Combined Glucosamine and Chondroitin Sulfate, Once of Three Times Daily, Provide Clinically Relevant Analgesia in Knee Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].